{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T18:16:07Z","timestamp":1759601767364},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,3,2]],"date-time":"2013-03-02T00:00:00Z","timestamp":1362182400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s00277-013-1711-7","type":"journal-article","created":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T18:20:35Z","timestamp":1362162035000},"page":"935-943","source":"Crossref","is-referenced-by-count":19,"title":["Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"92","author":[{"given":"Zhiyong","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junmin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,2]]},"reference":[{"key":"1711_CR1","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1517\/14656566.5.6.1321","volume":"5","author":"PG Richardson","year":"2004","unstructured":"Richardson PG (2004) A review of the proteasome inhibitor bortezomib in multiple myeloma. Expert Opin Pharmacother 5:1321\u20131331","journal-title":"Expert Opin Pharmacother"},{"key":"1711_CR2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.beha.2007.09.003","volume":"20","author":"MV Mateos","year":"2007","unstructured":"Mateos MV, San Miguel JF (2007) Bortezomib in multiple myeloma. Best Pract Res Clin Haematol 20:701\u2013715","journal-title":"Best Pract Res Clin Haematol"},{"key":"1711_CR3","unstructured":"Anderson KC, Anderson M, Bensinger W, Biermann JS, National Comprehensive Cancer Network (2009) Clinical practice guidelines in oncology\u2014multiple myeloma (version 2.2009). http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/myeloma.pdf . Accessed 20 Mar 2009"},{"key":"1711_CR4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/00003495-200969070-00006","volume":"69","author":"MP Curran","year":"2009","unstructured":"Curran MP, McKeage K (2009) Bortezomib: a review of its use in patients with multiple myeloma. Drugs 69:859\u2013888","journal-title":"Drugs"},{"key":"1711_CR5","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","volume":"101","author":"N Mitsiades","year":"2003","unstructured":"Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101:2377\u20132380","journal-title":"Blood"},{"key":"1711_CR6","doi-asserted-by":"crossref","first-page":"8386","DOI":"10.1038\/sj.onc.1207170","volume":"22","author":"T Hideshima","year":"2003","unstructured":"Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, Anderson KC (2003) Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22:8386\u20138393","journal-title":"Oncogene"},{"key":"1711_CR7","first-page":"3071","volume":"61","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071\u20133076","journal-title":"Cancer Res"},{"key":"1711_CR8","first-page":"1136","volume":"9","author":"MH Ma","year":"2003","unstructured":"Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adams J, Sjak-Shie N, Vescio RA, Berenson JR (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9:1136\u20131144","journal-title":"Clin Cancer Res"},{"key":"1711_CR9","first-page":"4996","volume":"62","author":"R LeBlanc","year":"2002","unstructured":"LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62:4996\u20135000","journal-title":"Cancer Res"},{"key":"1711_CR10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/jjco\/hyp046","volume":"39","author":"HS Eom","year":"2009","unstructured":"Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y (2009) Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma. Jpn J Clin Oncol 39:449\u2013455","journal-title":"Jpn J Clin Oncol"},{"key":"1711_CR11","first-page":"4960-","volume":"114","author":"D Lebon","year":"2009","unstructured":"Lebon D et al (2009) Bortezomib, doxorubicin and dexamethasone (PAD) prior to high-dose melphalan\/autologous stem cell transplantation for newly diagnosed plasma cell dycrasias. Blood (ASH Annual Meeting Abstracts) 114:4960-","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"1711_CR12","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906\u2013917","journal-title":"N Engl J Med"},{"key":"1711_CR13","unstructured":"Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration."},{"key":"1711_CR14","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","volume":"17","author":"MK Parmar","year":"1998","unstructured":"Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815\u20132834","journal-title":"Stat Med"},{"key":"1711_CR15","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1002\/sim.1303","volume":"21","author":"PR Williamson","year":"2002","unstructured":"Williamson PR, Smith CT, Hutton JL, Marson AG (2002) Aggregate data meta-analysis with time-to-event outcomes. Stat Med 21:3337\u20133351","journal-title":"Stat Med"},{"key":"1711_CR16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16","journal-title":"Trials"},{"key":"1711_CR17","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558","journal-title":"Stat Med"},{"key":"1711_CR18","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","volume":"28","author":"MV Mateos","year":"2010","unstructured":"Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Esseltine DL, Liu K, Cakana A, van de Velde H, San Miguel JF (2010) Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 28:2259\u20132266","journal-title":"J Clin Oncol"},{"key":"1711_CR19","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"M Cavo","year":"2010","unstructured":"Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376:2075\u20132085","journal-title":"Lancet"},{"key":"1711_CR20","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","volume":"120","author":"L Rosinol","year":"2012","unstructured":"Rosinol L, Oriol A, Teruel AI, Hernandez D, Lopez-Jimenez J, de la Rubia J, Granell M, Besalduch J, Palomera L, Gonzalez Y, Etxebeste MA, Diaz-Mediavilla J, Hernandez MT, de Arriba F, Gutierrez NC, Martin-Ramos ML, Cibeira MT, Mateos MV, Martinez J, Alegre A, Lahuerta JJ, San Miguel J, Blade J (2012) Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study. Blood 120:1589\u20131596","journal-title":"Blood"},{"key":"1711_CR21","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","volume":"28","author":"JL Harousseau","year":"2010","unstructured":"Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, Lenain P, Hulin C, Facon T, Casassus P, Michallet M, Maisonneuve H, Benboubker L, Maloisel F, Petillon MO, Webb I, Mathiot C, Moreau P (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 28:4621\u20134629","journal-title":"J Clin Oncol"},{"key":"1711_CR22","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J Clin Oncol 30:2946\u20132955","journal-title":"J Clin Oncol"},{"key":"1711_CR23","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0140-6736(93)93004-K","volume":"341","author":"LA Stewart","year":"1993","unstructured":"Stewart LA, Parmar MK (1993) Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 341:418\u2013422","journal-title":"Lancet"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1711-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-013-1711-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1711-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:49:41Z","timestamp":1559036981000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-013-1711-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,2]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["1711"],"URL":"https:\/\/doi.org\/10.1007\/s00277-013-1711-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,2]]}}}